Boston Scientific beats Q3 expectations, raises 2025 guidance amid strong performance in key franchises like WATCHMAN and FARAPULSE/pulsed-field ablation.
ECB holds rates, signaling end of easing cycle as eurozone outlook improves.
Boston Scientific beats Q3 expectations, raises 2025 guidance amid strong performance in key franchises like WATCHMAN and FARAPULSE/pulsed-field ablation.
ECB holds rates, signaling end of easing cycle as eurozone outlook improves.